B2M and Alzheimer disease: Blocking CD8 no alternation of cognitive outcome or plaque pathology (Merlini et al., 2018); Blocking CD3 improves spatial memory (Unger et al., 2020); β2m-deficiency alleviates AD (Fernando et al., 2023); β2m-deficiency exacerbates AD (Su et al., 2023).